The 2025 Canadian Paediatric Surveillance Program Annual Results are now available

This year’s report includes preliminary findings from multi-year studies on acute life-threatening harms related to illicit or non-medical use of opioids, stimulants and sedatives, severe neonatal hyperbilirubinemia, and non-medical cannabis use. The report also presents final results on adverse events related to virtual care and hyperglycemic hyperosmolar state, as well as findings from three one-time surveys. One of these surveys, which examined serious injuries and deaths involving powered personal mobility devices such as e-scooters and e-bikes, has drawn significant media attention since the official release of the 2025 CPSP Annual Results on August 13.

We would like to sincerely thank all who participated in the program in 2025 and continue to report in 2026. 

On May 1st, the Canadian Paediatric Surveillance Program (CPSP) launched 3 new multi-year studies on:

• Tick-borne diseases (excluding Lyme disease). This study will examine the epidemiology, presentation and outcomes of pediatric tick-borne diseases in Canada, helping to identify emerging trends and support greater clinical awareness of these infections.
• Severe hypernatremic dehydration in term and late preterm neonates. This study aims to better understand the factors associated with severe hypernatremic dehydration in newborns and identify opportunities for earlier recognition and prevention.
• Probiotic sepsis in infants under 2 years of age. This study will gather national data on cases of probiotic-associated sepsis in young children to help inform safer probiotic use and support improved clinical care for affected infants.

If you have seen any cases of these conditions, or any of the other conditions on our current list of studies, please report it to the CPSP.